GlassScriptPhysician profile
Melissa A Munsell
NPI 1134276272
$3,680.21
in general payments reported to CMS, 2019-2025
25 companies · $945 in 2025
The $945 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.61 · 2022: $895 · 2023: $817 · 2024: $1,002 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,682 · Education: $81.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,681.84 |
| Education | $81.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,611.55 | 2021-2025 | |
| Janssen Biotech, INC. | $453.79 | 2022-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $196.34 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $196.05 | 2022-2024 | Dificid |
| Madrigal Pharmaceuticals | $169.36 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $147.27 | 2022-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.80 | 2022-2024 | Xifaxan, Trulance |
| Ipsen Biopharmaceuticals, INC | $95.48 | 2024-2025 | Iqirvo, Bylvay |
| Janssen Scientific Affairs, LLC | $73.47 | 2024 | Stelara |
| Intercept Pharmaceuticals, INC. | $65.35 | 2023-2024 | Ocaliva |
| Pfizer INC. | $59.24 | 2024-2025 | |
| Fresenius Kabi USA, LLC | $58.68 | 2023 | |
| Genzyme Corporation | $49.53 | 2022-2025 | |
| Organon LLC | $49.10 | 2022-2023 | Hadlima |
| Celltrion USA INC. | $45.03 | 2024 | Zymfentra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $42.45 | 2023-2025 | Voquezna |
| Lilly USA, LLC | $40.23 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $39.26 | 2023-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $38.78 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $25.42 | 2025 | Vowst |
| Qol Medical, LLC | $22.86 | 2022 | |
| Redhill Biopharma INC. | $20.15 | 2023 | Talicia |
| Regeneron Healthcare Solutions, INC. | $18.42 | 2023 | Dupixent |
| Intra-Sana Laboratories | $16.21 | 2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Ferring Pharmaceuticals INC. | $14.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Munsell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.